First-Line Nivolumab plus Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743

被引：0

作者：

Baas, P. ^{[1
,2
]}

Scherpereel, A. ^{[3
]}

Nowak, A. ^{[4
]}

Fujimoto, N. ^{[5
]}

Peters, S. ^{[6
]}

Tsao, A. ^{[7
]}

Mansfield, A. ^{[8
]}

Popat, S. ^{[9
]}

Jahan, T. ^{[10
]}

Antonia, S. ^{[11
]}

Oulkhouir, Y. ^{[12
]}

Bautista, Y. ^{[13
]}

Cornelissen, R. ^{[14
]}

Greillier, L. ^{[15
]}

Grossi, F. ^{[16
]}

Kowalski, D. M. ^{[17
]}

Rodriguez-Cid, J. ^{[18
]}

Aanur, P. ^{[19
]}

Baudelet, C. ^{[19
]}

Zalcman, G. ^{[20
]}

机构：

[1] Netherlands Canc Inst, Amsterdam, Netherlands

[2] Leiden Univ, Amsterdam, Netherlands

[3] Univ Lille, CHU Lille, INSERM U1189, Pulm & Thorac Oncol,OncoThAI, Lille, France

[4] Univ Western Australia, Perth, WA, Australia

[5] Okayama Rosai Hosp, Okayama, Japan

[6] Lausanne Univ Hosp, Lausanne, Switzerland

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Mayo Clin, Rochester, MN USA

[9] Royal Marsden Hosp, London, England

[10] USCF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[12] CHU Caen, Hop Cote De Nacre, Caen, France

[13] Ctr Med Nacl Siglo XXI, Mexico City, DF, Mexico

[14] Erasmus MC Canc Inst, Rotterdam, Netherlands

[15] Aix Marseille Univ, Marseille, France

[16] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[17] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[18] Ctr Oncol Med Sur, Mexico City, DF, Mexico

[19] Bristol Myers Squibb Co, Princeton, NJ USA

[20] Univ Paris Diderot, Paris, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2908

引用

页码：E42 / E42

页数：1

共 50 条

[41] Cost-effectiveness of nivolumab and ipilimumab versus chemotherapy (with and without bevacizumab) in patients with unresectable malignant pleural mesothelioma in Switzerland
Barbier, M. C.
Fengler, A.
Gautschi, O.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S118 - S118
[42] First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma
Fujimoto, Eriko
Kijima, Takashi
Kuribayashi, Kozo
Negi, Yoshiki
Kanemura, Shingo
Mikami, Koji
Doi, Hiroshi
Kitajima, Kazuhiro
Nakano, Takashi
EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (09) : 865 - 872
[43] First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma
Fujimoto, E.
Kuribayashi, K.
Kanemura, S.
Negi, Y.
Koda, Y.
Mikami, K.
Minami, T.
Yokoi, T.
Nakano, T.
Kijima, T.
ANNALS OF ONCOLOGY, 2017, 28
[44] CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC
Antonia, Scott J.
Gettinger, Scott N.
Goldman, Jonathan
Brahmer, Julie
Borghaei, Hossein
Chow, Laura Q.
Ready, Neal E.
Gerber, David E.
Juergens, Rosalyn
Shepherd, Frances
Laurie, Scott A.
Young, Tina
Geese, William J.
Agrawal, Shruti
Li, Xuemei
Hellmann, Matthew D.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S250 - S251
[45] Ipilimumab and Nivolumab in Pretreated Patients with Malignant Pleural Mesothelioma
Jakopovic, M.
Seiwerth, F.
Bitar, L.
Ljubicic, L.
Maletic, O.
Karabatic, S.
Samarzija, M.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S318 - S318
[46] Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting
Shah, Rajiv
Reck, Martin
Grohe, Christian
Christoph, Daniel Christian
Buchmeier, Eva Lotte
Saalfeld, Felix Carl
Frost, Nikolaj
Kopp, Hans-Georg
Faehling, Martin
Griesinger, Frank
Roeper, Julia
Hoffknecht, Petra
Kuon, Jonas
Luan, Jingting
Chesi, Paolo
Christopoulos, Petros
Thomas, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[47] First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401
Dummer, Reinhard
Corrie, Pippa
Gutzmer, Ralf
Meniawy, Tarek M.
Del Vecchio, Michele
Lebbe, Celeste
Guida, Michele
Dutriaux, Caroline
Dreno, Brigitte
Meyer, Nicolas
Ferrucci, Pier Francesco
Dalle, Stephane
Khattak, Muhammad Adnan
Grob, Jean-Jacques
Briscoe, Karen
Larkin, James
Mansard, Sandrine
Lesimple, Thierry
Guidoboni, Massimo
Sabatini, Silvia
Richtig, Erika
Herbst, Rudolf
Lobo, Maurice
Askelson, Margarita
Ascierto, Paolo A.
Maio, Michele
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (23) : 3917 - +
[48] eVOLVE-Meso: A Global Phase 3 Study of First-Line Volrustomig Plus Chemotherapy in Unresectable Pleural Mesothelioma
Scherpereel, A.
Fennell, D. A.
Fujimoto, N.
Marmarelis, M. E.
Tsao, A.
Aerts, J.
Li, X.
Dalvi, T.
Jiang, H.
Krug, L.
Zauderer, M.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S281 - S281
[49] Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
Galle, Peter Robert
Decaens, Thomas
Kudo, Masatoshi
Qin, Shukui
Fonseca, Leonardo
Sangro, Bruno
Karachiwala, Hatim
Park, Joong-Won
Gane, Edward
Pinter, Matthias
Tai, David
Santoro, Armando
Pizarro, Gonzalo
Chiu, Chang-Fang
Schenker, Michael
He, Aiwu Ruth
Wang, Qi
Stromko, Caitlyn
Hreiki, Joseph
Yau, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA4008 - LBA4008
[50] STELLAR Trial: Radiological Response Patterns of TTFields Plus Chemotherapy in First-Line Treatment of Malignant Pleural Mesothelioma
Grosso, F.
Aerts, J.
Ramlau, R.
Cedres, S.
Mencoboni, M.
Van Meerbeeck, J.
Dziadziuszko, R.
Planchard, D.
Chella, A.
Crino, L.
Krzakowski, M.
Ceresoli, G. L.
Weinberg, U.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S755 - S755

← 1 2 3 4 5 →